Ernesto Aycardi-Fonseca Net Worth

Ernesto Aycardi-Fonseca biography

Dr. Ernesto Aycardi-Fonseca M.D. serves as Chief Medical Officer of the Company. Dr Aycardi is employed by our wholly owned subsidiary, Xenon Pharmaceuticals USA Inc. and has served as our Chief Medical Officer since March 2018. Prior to joining us, Dr. Aycardi was at Teva Pharmaceutical from 2014 to 2018, most recently as Vice-President and Head of Clinical Trial Operations, Biostatistics & Data Sciences and Clinical Pharmacology. Prior to this, he was Teva Pharmaceutical’s Vice-President, Therapeutic Area Head, Clinical Development, Migraine and Headache from 2016 to 2017, and previously Teva Pharmaceutical’s Senior Director, Clinical Development, Migraine & Headache from 2014 to 2016. From 2013 to 2014, Dr. Aycardi was Senior Director Head of Neuro-Degenerative Disorders for EMD Serono, Inc. Previously, he was Director, Medical Research focused on neurology development at Biogen Idec from 2009 to 2013. Dr. Aycardi held a series of roles with increasing responsibility at Merck from 1998 to 2009, both in Colombia and in the United States, where he was Worldwide Clinical Research Senior Director for various therapeutic areas throughout late phases of global drug development from 2006 to 2009. Having received his M.D. from the National University of Colombia, and neurology training at the Military Hospital in Colombia, Dr. Aycardi holds a current medical license in Colombia, and was a practicing neurologist beginning in 1993.

What is the salary of Ernesto Fonseca?

As the Chief Medical Officer of Xenon Pharmaceuticals Inc, the total compensation of Ernesto Fonseca at Xenon Pharmaceuticals Inc is $1,072,980. There are 2 executives at Xenon Pharmaceuticals Inc getting paid more, with Simon Pimstone having the highest compensation of $2,612,720.

How old is Ernesto Fonseca?

Ernesto Fonseca is 57, he's been the Chief Medical Officer of Xenon Pharmaceuticals Inc since 2018. There are 13 older and 9 younger executives at Xenon Pharmaceuticals Inc. The oldest executive at Xenon Pharmaceuticals Inc is Michael Tarnow, 74, who is the Independent Chairman of the Board.

What's Ernesto Fonseca's mailing address?

Ernesto's mailing address filed with the SEC is 200 - 3650 GILMORE WAY, , BURNABY, A1, .

Insiders trading at Xenon Pharmaceuticals Inc

Over the last 10 years, insiders at Xenon Pharmaceuticals Inc have traded over $12,977,011 worth of Xenon Pharmaceuticals Inc stock and bought 724,015 units worth $2,649,316 . The most active insiders traders include Patrick Machado, Partners L P/Ilbiotechnolog... a Justin D. Gover. On average, Xenon Pharmaceuticals Inc executives and independent directors trade stock every 31 days with the average trade being worth of $818,878. The most recent stock trade was executed by Elizabeth A. Garofalo on 8 March 2024, trading 3,500 units of XENE stock currently worth $64,960.

What does Xenon Pharmaceuticals Inc do?

xenon® (nasdaq: xene) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as extreme genetics. our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. we apply our expertise to predict which phenotypes are caused by single-gene defects. by identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.

Xenon Pharmaceuticals Inc executives and stock owners

Xenon Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Simon Pimstone,
  Chief Executive Officer, Director
• Ian Mortimer,
  President, Chief Financial Officer, Corporate Secretary
• Ernesto Aycardi-Fonseca,
  Chief Medical Officer
• Dr. Simon N. Pimstone FRCPC, M.B. ChB., M.D., Ph.D.,
  Exec. Chairman
• Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA,
  Pres, CEO & Director
• Robin Sherrington,
  Executive Vice President - Strategy & Innovation
• James Empfield,
  Senior Vice President - Drug Discovery
• Dr. Christopher John Kenney M.D.,
  Chief Medical Officer
• Michael Tarnow,
  Independent Chairman of the Board
• Dawn Svoronos,
  Independent Director
• Gary Patou,
  Independent Director
• Frank Holler,
  Independent Director
• Michael Hayden,
  Independent Director
• Steven Gannon,
  Independent Director
• Clarissa Desjardins,
  Independent Director
• Mohammad Azab,
  Independent Director
• Shelley McCloskey,
  Senior Vice President - Human Resources
• Dr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D.,
  Chief Commercial Officer
• Dr. Kenneth Sommerville,
  Interim Chief Medical Officer
• Dr. Christopher E. Von Seggern M.B.A., M.P.H., Ph.D., M.P.H. M.B.A,
  Chief Commercial Officer
• Sheila M. Grant M.B.A., M.Sc., MBA,
  Sr. VP of R&D Operations
• Dr. James R. Empfield,
  Exec. VP of Drug Discovery
• Dr. Robin P. Sherrington,
  Exec. VP of Strategy & Innovation
• Shelley McCloskey B.A.,
  Sr. VP of HR
• Jodi Regts M.B.A., B.A., MBA,
  VP of Corp. Affairs & Investor Relations
• Sherry Aulin,
  Chief Financial Officer
• Charles J. Cohen,
  VP, Biology
• Raymond Winquist,
  Head, Translational Research
• Partners L P/Ilbiotechnolog...,
  
• Richard H Scheller,
  Director
• Christopher John Kenney,
  Chief Medical Officer
• Sherry Aulin,
  Chief Financial Officer
• Seggern Christopher Von,
  Chief Commercial Officer
• Elizabeth A. Garofalo,
  
• Patrick Machado,
  
• Y. Paul Goldberg,
  VP, Clinical Development
• Associates, Llp Mx,
  10% owner
• Karen G. Corraini,
  Gen. Counsel & Corp. Secretary
• Johnston L Evans,
  Director
• Evan A. Stein,
  Director
• Gary Bridger,
  EVP, Research & Development
• Gillian Cannon,
  
• Justin D. Gover,